Stock listing

NASDAQ:ORKA Oruka Therapeutics, Inc. Stock

Home listing (NASDAQ) of Oruka Therapeutics, Inc.

Follow Oruka Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ORKA

$95.81 USD +0.07 (+0.1%)

Close on Nov 20, 2026

Past year +255.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$93.30 – $97.24 USDNov 20, 2026
Volume
1.98M sharesNov 20, 2026
Market cap
$6.50B USDAt the close on Nov 20, 2026 · price × 67.82M shares outstanding
52-week range
$25.23 – $115.52 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$88.52M USDMedian day 822,160 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Oruka Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ORKA · Home$95.81 USD+0.07 (+0.1%)1,977,006$95.86$97.24$93.30$95.74Close on Nov 20, 2026
Frankfurt:HQ1€88.00 EUR+1.00 (+1.1%)—€88.00€88.00€88.00€87.00Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ORKA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$95.81+0.07+0.1%$95.86$97.24$93.301,977,006
$95.74-0.58-0.6%$96.31$99.11$95.07521,772
$96.32-2.92-2.9%$98.51$100.77$95.05780,179
$99.24-6.11-5.8%$104.10$107.50$98.89989,987
$105.35+0.36+0.3%$104.89$106.87$101.56679,677
$104.99-2.18-2.0%$105.10$107.00$101.501,141,814
$107.17-2.33-2.1%$112.28$112.42$106.26844,076
$109.50+4.94+4.7%$103.84$113.24$102.782,611,570
$104.56+1.70+1.7%$104.56$108.08$103.461,598,894
$102.86+6.84+7.1%$97.99$103.75$96.051,070,244
$96.02-5.39-5.3%$100.02$100.73$94.05846,558
$101.41+1.86+1.9%$102.37$102.59$96.34790,242
$99.55+4.12+4.3%$97.48$101.41$95.29822,160
$95.43-1.44-1.5%$98.85$99.83$94.29654,335
$96.87+0.22+0.2%$94.87$97.60$94.75633,810
$96.65+0.68+0.7%$97.04$98.88$95.26657,177
$95.97+0.16+0.2%$95.26$98.45$94.17798,075
$95.81+5.48+6.1%$89.02$96.59$89.021,205,199
$90.33+10.18+12.7%$81.98$93.42$81.981,942,729
$80.15-1.00-1.2%$81.15$81.15$79.07514,000
$81.15+1.23+1.5%$79.06$82.15$78.36589,900
$79.92+0.83+1.0%$79.97$81.75$79.48953,400
$79.09+4.61+6.2%$74.42$79.90$74.42787,700
$74.48+2.55+3.5%$72.40$76.35$72.30812,700
$71.93-1.94-2.6%$73.75$74.26$70.501,388,200
$73.87-2.81-3.7%$75.53$77.89$73.151,222,100
$76.68-1.51-1.9%$77.37$78.57$75.41685,300
$78.19-2.16-2.7%$79.47$80.19$78.18503,100
$80.35-1.76-2.1%$81.81$82.95$79.43547,900
$82.11+4.83+6.2%$77.24$82.24$77.001,206,700
$77.28-2.22-2.8%$78.47$80.19$75.831,225,000
$79.50-0.68-0.8%$79.01$81.40$78.52809,900
$80.18-4.20-5.0%$84.94$84.94$77.781,122,000
$84.38-0.14-0.2%$84.52$85.23$81.83629,600
$84.52+1.10+1.3%$84.81$86.00$83.33581,500
$83.42+0.13+0.2%$82.85$85.00$82.50921,000
$83.29+1.14+1.4%$83.33$86.51$82.271,535,600
$82.15-2.04-2.4%$83.32$84.67$81.111,363,300
$84.19-0.27-0.3%$83.94$85.95$83.22923,300
$84.46-1.03-1.2%$86.49$86.49$84.00499,700
$85.49-4.44-4.9%$88.83$89.18$82.701,294,400
$89.93-4.62-4.9%$94.08$95.81$85.001,993,000
$94.55+1.17+1.3%$93.38$96.78$91.531,054,900
$93.38-1.58-1.7%$95.75$96.00$91.751,185,400
$94.96-2.77-2.8%$98.18$98.29$94.521,943,000
$97.73+4.18+4.5%$94.93$98.02$94.051,046,900
$93.55+1.35+1.5%$92.70$95.46$92.19927,000
$92.20-3.73-3.9%$95.14$95.81$90.41784,600
$95.93+3.55+3.8%$92.56$97.48$92.55773,800
$92.38+0.73+0.8%$93.40$94.29$90.48585,300
$91.65+0.15+0.2%$90.21$92.29$88.07554,600
$91.50-2.81-3.0%$93.59$94.85$91.23525,000
$94.31+1.80+1.9%$90.06$96.44$87.68868,300
$92.51+1.52+1.7%$90.06$94.00$89.38600,500
$90.99-0.64-0.7%$91.72$93.69$90.12732,600
$91.63-0.48-0.5%$93.05$96.20$89.88671,700
$92.11-0.51-0.6%$90.78$93.20$90.27596,200
$92.62+1.47+1.6%$91.00$93.88$86.001,292,900
$91.15-5.39-5.6%$95.08$95.45$91.01589,400
$96.54-2.90-2.9%$98.93$99.62$96.16614,600
$99.44-2.38-2.3%$101.30$102.48$98.24526,700
$101.82-0.60-0.6%$104.74$106.91$100.291,308,022
$102.42-5.54-5.1%$106.75$107.23$100.64992,276
$107.96+3.10+3.0%$105.48$109.52$103.86935,800
$104.86-4.83-4.4%$107.72$109.01$103.14778,900

Splits

6 splits since 2004 · NASDAQ:ORKA · every price before a split is adjusted for it

DayRatioWhat
1-for-12Consolidation
1-for-18Consolidation
1-for-7Consolidation
1-for-6Consolidation
1-for-20Consolidation
1-for-3Consolidation
Ticker
NASDAQ:ORKA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Oruka Therapeutics, Inc. news

Oruka Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
20 in the last 12 months · 87 in all · newest Nov 9, 2026 · oldest 2019
Decks
23 decks · latest November 2026

Where Oruka Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ORKA · Home listing · This pageNASDAQUnited StatesUSD
gettex:HQ1gettexGermanyEUR
BOATS:ORKABOATSUnited StatesUSD
LS Exchange:A3DPH3LS ExchangeGermanyEUR
Lang & Schwarz:A3DPH3Lang & SchwarzGermanyEUR
Tradegate:HQ1TradegateGermanyEUR
Dusseldorf:HQ1DusseldorfGermanyEUR
Munich:HQ1MunichGermanyEUR
Frankfurt:HQ1FrankfurtGermanyEUR
Stuttgart:HQ1StuttgartGermanyEUR
Hamburg:HQ1HamburgGermanyEUR
Hanover:HQ1HanoverGermanyEUR
Xetra:HQ1XetraGermanyEUR

Cash and shares

Jul 31, 2026 · Oruka Therapeutics — Investor Presentation (October 2026)

Shares outstanding
66.2 million

The slide these figures come from

Valuation

Price/book 5.4× against a median of 24.9×: 2nd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$5.58B USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
5.4×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.30

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Oruka Therapeutics, Inc. · NASDAQ:ORKAUS$6.50BUS$5.58Bn/an/an/a5.4×n/a0.0×1.30
CG Oncology, Inc. · NASDAQ:CGONUS$7.10BUS$6.12Bn/a992×n/a7.2×n/a0.0×0.83
Cytokinetics, Incorporated · NASDAQ:CYTKUS$7.07BUS$6.36Bn/a56.2×n/an/a−686.6%n/a0.93
Axsome Therapeutics, Inc. · NASDAQ:AXSMUS$6.80BUS$6.68Bn/a7.7×n/a64.5×−18.2%1.8×0.69
Akeso, Inc. · HKEX:9926US$6.66BUS$6.04Bn/a13.5×n/a5.2×−36.4%0.6×n/a
Immunovant, Inc. · NASDAQ:IMVTUS$6.57BUS$5.85Bn/a825×n/a10.0×n/a0.0×1.46
ImmunityBio, Inc. · NASDAQ:IBRXUS$6.40BUS$6.10Bn/a33.4×n/an/a−607.8%n/a1.50
Kodiak Sciences Inc · NASDAQ:KODUS$6.35BUS$6.31Bn/an/an/a505×n/a3.7×1.58
Abivax SA · EURONEXT:ABVXUS$6.05BUS$5.60Bn/an/an/a15.1×n/a0.0×n/a
Scholar Rock Holding Corporation · NASDAQ:SRRKUS$5.87BUS$5.65Bn/a9,921×n/a34.8×n/a1.2×0.91
Arrowhead Pharmaceuticals, Inc. · NASDAQ:ARWRUS$5.85BUS$4.66Bn/a10.3×n/a116×−160.6%0.0×1.34
Median of the othersUS$6.49BUS$6.07B44.8×24.9×−160.6%0.3×1.14

Forecasts

11 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
156.17 USD · Analysts' mean
EPS, year to Dec 2026
-2.52 · 6 analysts

Team and board

Officers

OfficerRole
Todd EdwardsChief Commercial Officer

Board

DirectorRole
Carl DambkowskiDirector
Chris MartinDirector
Kristine BallDirector
Peter HarwinDirector
Samarth KulkarniDirector

Events

QuarterResultsShare move
Q3 2026Nov 9, 2026 · After close+4.7%
Q2 2026Aug 10, 2026 · Before open+6.4%
Q1 2026May 13, 2026 · After close+1.1%
Q4 2025Mar 13, 2026+30.5%
Q3 2025Nov 12, 2025 · After close−6.8%
Q2 2025Aug 11, 2025 · After close+6.9%
Q1 2025May 14, 2025 · After close−2.6%
Q4 2024Mar 6, 2025+0.8%
Q3 2024Nov 13, 2024 · After close−6.4%
Q2 2024Aug 27, 2024 · Before open+1.8%
All 20 quarters
QuarterResultsShare move
Q1 2024Apr 25, 2024−1.4%
Q4 2023Feb 1, 2024+1.9%
Q3 2023Nov 7, 20230.0%
Q2 2023Jul 21, 20230.0%
Q1 2023Apr 24, 2023+1.0%
Q4 2022Feb 24, 2023+3.3%
Q3 2022Oct 28, 2022+2.9%
Q2 2022Aug 2, 2022−2.9%
Q1 2022May 2, 2022+1.7%
Q4 2021Mar 14, 2022+2.4%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck28 slidesNovember 2026
Corporate Update (October 2026)Corporate update21 slidesOct 26, 2026
Investor Presentation (October 2026)Investor deck28 slidesOctober 2026
Investor Presentation (September 2026)Investor deck30 slidesSeptember 2026
Investor Presentation (August 2026)Investor deck30 slidesAugust 2026
Investor Presentation (June 2026)Investor deck29 slidesJune 2026
Investor Presentation (May 2026)Investor deck29 slidesMay 2026
Technical Presentation (April 2026)Technical22 slidesApr 27, 2026
Investor Presentation (March 2026)Investor deck36 slidesMarch 2026
Investor Presentation (January 2026)Investor deck38 slidesJanuary 2026
All 23 decks
DeckKindSlidesDate
Investor Presentation (November 2025)Investor deck38 slidesNovember 2025
Investor Presentation (September 2025)Investor deck38 slidesSeptember 2025
Investor Presentation (July 2025)Investor deck35 slidesJuly 2025
Investor Presentation (May 2025)Investor deck34 slidesMay 20, 2025
Investor Presentation (May 2025)Investor deck33 slidesMay 2025
Investor Presentation (March 2025)Investor deck33 slidesMarch 2025
Investor Presentation (February 2025)Investor deck36 slidesFebruary 2025
Investor Presentation (January 2025)Investor deck35 slidesJanuary 2025
Investor Presentation (November 2024)Investor deck31 slidesNovember 2024
ARCA biopharma — Merger or Acquisition (August 2024)Merger or acquisition31 slidesAug 9, 2024
ARCA biopharma — Merger or Acquisition (June 2024)Merger or acquisition30 slidesJun 6, 2024
ARCA biopharma — Merger or Acquisition (April 2024)Merger or acquisition30 slidesApr 3, 2024
Variagenics — Merger or Acquisition (January 2003)Merger or acquisition14 slidesJan 28, 2003

Open Decks

Financings

RaiseDate
Public offering of common stock
Made bigger: about US$700.4M · US$72.5 a share · Leerink Partners +5
Dealers: Leerink Partners (co-lead), TD Cowen (co-lead), Goldman Sachs & Co. LLC (co-lead), Stifel (co-lead), Guggenheim Securities (co-lead), LifeSci Capital
Apr 28, 2026
Private placement of common stock and pre-funded warrants
Closed: US$180M raised · US$15 a share · Jefferies +3
Dealers: Jefferies (co-lead), TD Cowen (co-lead), Guggenheim Securities (co-lead), LifeSci Capital (co-lead)
Buyers: Viking Global Investors (led the PIPE financing); Affinity Healthcare Fund; Blackstone Multi-Asset Investing; Commodore Capital; Cormorant Asset Management; Deep Track Capital; Fairmount; Great Point Partners, LLC; Palo Alto Investors, LP; Perceptive Advisors; Surveyor Capital; Venrock Healthcare Capital Partners
Use of proceeds: Extend cash runway over one year past three Phase 2 readouts (ORKA-001 Phase 2a and 2b, ORKA-002 Phase 2)
Nov 12, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue000000000
Cost of revenue83.0K27.0K111.0K114.0K91.0K93.0K89.0K22.0K27.0K24.0K
Gross profit-83.0K-27.0K-111.0K-114.0K-91.0K-93.0K-89.0K-22.0K-27.0K-24.0K
Research and development100.6M75.1M1.01M4.75M13.8M4.99M1.83M4.24M14.1M12.3M
Selling, general and administrative21.4M
Operating income-122.1M-88.1M-7.30M-10.6M-19.3M-9.77M-5.81M-8.12M-18.7M-16.6M
Depreciation and amortization83.0K27.0K15.0K20.0K16.0K8.00K18.0K22.0K27.0K24.0K
EBITDA-122.0M-88.1M-7.28M-10.6M-19.3M-9.76M-5.80M-8.10M-18.7M-16.6M
Interest expense01.47M9.00K7.00K8.00K6.00K
Income before tax-105.4M-83.7M-5.34M-9.93M-19.3M-9.75M-5.65M-7.96M-18.6M-16.4M
Income tax000-9.00K-167.0K-31.0K-61.0K0
Net income-105.4M-83.7M-5.34M-9.93M-19.3M-9.74M-5.48M-7.93M-18.5M-16.4M
Earnings per share, basic-2.16-4.99-0.37-0.69-1.39-2.07-4.15-10.31-1.77-1.81
Earnings per share, diluted-0.37-0.69-1.39-2.07-4.15-10.31-1.77-1.81

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents46.9M61.6M37.4M42.4M53.4M49.1M8.36M6.61M8.70M7.40M
Short-term investments290.1M314.1M3.05M13.8M
Current assets343.9M376.9M37.6M42.7M54.4M50.0M8.48M6.78M12.3M21.4M
Property, plant and equipment288.0K10.0K25.0K48.0K21.0K10.0K24.0K42.0K66.0K
Total assets488.6M396.0M37.9M43.1M54.9M50.4M8.54M6.83M12.4M24.6M
Accounts payable4.16M3.46M362.0K334.0K1.12M1.77M418.0K230.0K622.0K1.21M
Current liabilities15.4M13.0M637.0K1.13M3.50M3.50M926.0K793.0K2.07M2.40M
Total debt1.93M968.0K00000000
Total liabilities16.7M13.8M841.0K1.41M3.88M3.91M926.0K793.0K2.09M2.44M
Shareholders' equity471.9M382.2M37.0M41.7M51.0M46.5M7.61M6.03M10.3M22.2M
Shares outstanding48.7M16.8M14.5M14.4M14.4M9.55M1.59M773.6K11.8M9.08M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-88.2M-57.8M-5.01M-10.9M-18.8M-7.72M-4.80M-8.24M-17.5M-15.0M
Capital spending-209.0K-189.0K0-2.00K-43.0K-19.0K-4.00K-4.00K-3.00K-12.0K
Free cash flow-88.4M-58.0M-5.01M-10.9M-18.8M-7.74M-4.80M-8.25M-17.5M-15.0M
Cash from investing-96.7M-330.1M0-2.00K-43.0K-19.0K-4.00K3.05M12.9M-16.4M
Cash from financing170.3M449.5M0023.1M48.5M6.56M3.10M5.85M
Change in cash-14.6M24.1M-5.01M-10.9M4.29M40.7M1.75M-2.09M1.30M-31.4M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 20, 2026Insider tradeSEC
144 · Notice of proposed saleNov 20, 2026Other filingsSEC
4 · Change in ownershipNov 16, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
144 · Notice of proposed saleNov 12, 2026Other filingsSEC
144 · Notice of proposed saleNov 12, 2026Other filingsSEC
10-Q · Quarterly reportNov 9, 2026Quarterly reportSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipNov 2, 2026Insider tradeSEC
144 · Notice of proposed saleNov 2, 2026Other filingsSEC
8-K · Current reportOct 26, 2026Current reportSEC
4 · Change in ownershipOct 20, 2026Insider tradeSEC
4 · Change in ownershipOct 15, 2026Insider tradeSEC
144 · Notice of proposed saleOct 15, 2026Other filingsSEC
4 · Change in ownershipOct 13, 2026Insider tradeSEC
144 · Notice of proposed saleOct 13, 2026Other filingsSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
144 · Notice of proposed saleOct 1, 2026Other filingsSEC
4 · Change in ownershipSep 21, 2026Insider tradeSEC
4 · Change in ownershipSep 21, 2026Insider tradeSEC
144 · Notice of proposed saleSep 21, 2026Other filingsSEC
4 · Change in ownershipSep 15, 2026Insider tradeSEC
4 · Change in ownershipSep 15, 2026Insider tradeSEC
4 · Change in ownershipSep 15, 2026Insider tradeSEC
4 · Change in ownershipSep 15, 2026Insider tradeSEC
4 · Change in ownershipSep 15, 2026Insider tradeSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
144 · Notice of proposed saleSep 1, 2026Other filingsSEC
144 · Notice of proposed saleSep 1, 2026Other filingsSEC
424B5 · ProspectusAug 28, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveAug 28, 2026Other filingsSEC
4 · Change in ownershipAug 25, 2026Insider tradeSEC
3 · Initial statement of ownershipAug 25, 2026Insider tradeSEC
8-K · Current reportAug 24, 2026Management or board changeSEC
S-3 · Registration statementAug 21, 2026Offer documentSEC
4 · Change in ownershipAug 17, 2026Insider tradeSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
144 · Notice of proposed saleAug 14, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 12, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 10, 2026Quarterly reportSEC
8-K · Current reportAug 10, 2026ResultsSEC
4 · Change in ownershipJul 15, 2026Insider tradeSEC
144 · Notice of proposed saleJul 15, 2026Other filingsSEC
4 · Change in ownershipJul 13, 2026Insider tradeSEC
144 · Notice of proposed saleJul 13, 2026Other filingsSEC
144 · Notice of proposed saleJul 1, 2026Other filingsSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 1, 2026Big-stake noticeSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
144 · Notice of proposed saleJun 11, 2026Other filingsSEC
8-K · Current reportJun 4, 2026Meeting outcomeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
4 · Change in ownershipJun 3, 2026Insider tradeSEC
8-K · Current reportJun 1, 2026Current reportSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
144 · Notice of proposed saleMay 21, 2026Other filingsSEC
4 · Change in ownershipMay 18, 2026Insider tradeSEC
144 · Notice of proposed saleMay 18, 2026Other filingsSEC
4 · Change in ownershipMay 15, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 4, 2026Big-stake noticeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
144 · Notice of proposed saleMay 1, 2026Other filingsSEC
8-K · Current reportApr 30, 2026ResultsSEC
424B5 · ProspectusApr 29, 2026Offer documentSEC
424B5 · ProspectusApr 27, 2026Offer documentSEC
424B5 · ProspectusApr 27, 2026Offer documentSEC
8-K · Current reportApr 27, 2026Current reportSEC
424B7 · ProspectusApr 21, 2026Offer documentSEC
ARS · Annual report to shareholdersApr 17, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 17, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 17, 2026Meeting noticeSEC
4 · Change in ownershipApr 15, 2026Insider tradeSEC
144 · Notice of proposed saleApr 15, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveApr 13, 2026Other filingsSEC
CORRESP · Letter to the SECApr 8, 2026Other filingsSEC
UPLOAD · Letter from the SECApr 7, 2026Other filingsSEC
S-3 · Registration statementApr 2, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 27, 2026Big-stake noticeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
4 · Change in ownershipMar 17, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMar 12, 2026Offer documentSEC
10-K · Annual reportMar 12, 2026Annual reportSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 17, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 30, 2026Big-stake noticeSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJan 21, 2026Big-stake noticeSEC
4 · Change in ownershipJan 16, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
144 · Notice of proposed saleJan 2, 2026Other filingsSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
144 · Notice of proposed saleDec 19, 2025Other filingsSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
3 · Initial statement of ownershipDec 11, 2025Insider tradeSEC
8-K · Current reportDec 11, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
424B3 · ProspectusNov 5, 2025Offer documentSEC
424B5 · ProspectusNov 5, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 17, 2025Big-stake noticeSEC
S-3/A · Registration statement, amendedOct 14, 2025Offer documentSEC
S-3/A · Registration statement, amendedOct 14, 2025Offer documentSEC
S-3 · Registration statementOct 3, 2025Offer documentSEC
S-3 · Registration statementOct 3, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeSep 24, 2025Big-stake noticeSEC
424B3 · ProspectusSep 22, 2025Offer documentSEC
8-K · Current reportSep 22, 2025Material contractSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 19, 2025Big-stake noticeSEC
4 · Change in ownershipSep 19, 2025Insider tradeSEC
424B3 · ProspectusAug 11, 2025Offer documentSEC
10-Q · Quarterly reportAug 11, 2025Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeJul 17, 2025Big-stake noticeSEC
4 · Change in ownershipJul 1, 2025Insider tradeSEC
3 · Initial statement of ownershipJul 1, 2025Insider tradeSEC
8-K · Current reportJul 1, 2025Management or board changeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
8-K · Current reportJun 3, 2025Meeting outcomeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2025Big-stake noticeSEC
424B3 · ProspectusMay 14, 2025Offer documentSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeMay 13, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 18, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 18, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 18, 2025Meeting noticeSEC
EFFECT · Notice that a registration is effectiveMar 12, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 10, 2025Big-stake noticeSEC
POS AM · Amendment to an effective registrationMar 6, 2025Offer documentSEC
S-8 · Registration statement for employee plansMar 6, 2025Offer documentSEC
10-K · Annual reportMar 6, 2025Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 27, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 27, 2025Insider tradeSEC
3 · Initial statement of ownershipFeb 27, 2025Insider tradeSEC
8-K · Current reportFeb 5, 2025Material contractSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
8-K · Current reportDec 19, 2024Material contractSEC
EFFECT · Notice that a registration is effectiveNov 27, 2024Other filingsSEC
CORRESP · Letter to the SECNov 22, 2024Other filingsSEC
UPLOAD · Letter from the SECNov 22, 2024Other filingsSEC
SC 13D/A · Big-stake notice, amendedNov 21, 2024Big-stake noticeSEC
4 · Change in ownershipNov 21, 2024Insider tradeSEC
8-K · Current reportNov 18, 2024Meeting outcomeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
S-8 · Registration statement for employee plansNov 14, 2024Offer documentSEC
8-K · Current reportNov 14, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
S-1 · Registration statementNov 14, 2024Offer documentSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
SC 13D/A · Big-stake notice, amendedOct 22, 2024Big-stake noticeSEC
DEF 14A · Proxy statementOct 18, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementOct 7, 2024Meeting noticeSEC
SC 13G · Big-stake noticeOct 7, 2024Big-stake noticeSEC
8-K · Current reportOct 4, 2024Management or board changeSEC
SC 13D/A · Big-stake notice, amendedSep 13, 2024Big-stake noticeSEC
4 · Change in ownershipSep 13, 2024Insider tradeSEC
8-K · Current reportSep 13, 2024Material contractSEC
SC 13D · Big-stake noticeSep 6, 2024Big-stake noticeSEC
3 · Initial statement of ownershipSep 6, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 6, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 6, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 6, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 6, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 6, 2024Insider tradeSEC

This page holds 200 of 1,002 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Oruka Therapeutics, Inc.’s releases · as of Oct 31, 2026

Common shares
67,822,359
Fully diluted
67,822,359

Fully diluted

LineSharesAs of
Common shares67,822,359Oct 31, 2026

Share count over time

CountShares
Oct 31, 202667,822,359

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Fidelity10.1MUS$845MSep 30, 2026
T. Rowe Price5.36MUS$446MSep 30, 2026
BlackRock5.21MUS$434MSep 30, 2026
Vanguard4.72MUS$394MSep 30, 2026
Venrock Adviser, LLC4.15MUS$346MSep 30, 2026
Fairmount Funds Management LLC3.71MUS$309MSep 30, 2026
Capital Group3.43MUS$286MSep 30, 2026
Rtw Investments, LP3.14MUS$261MSep 30, 2026
State Street2.82MUS$235MSep 30, 2026
Paradigm Biocapital Advisors LP2.49MUS$208MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Franklin Templeton2.03MUS$206MSep 30, 2026
Janus Henderson1.87MUS$156MSep 30, 2026
Bellevue Group AG1.64MUS$137MSep 30, 2026
Ra Capital Management, L.P.1.55MUS$129MSep 30, 2026
Geode Capital1.55MUS$129MSep 30, 2026
Polar Capital Holdings Plc1.22MUS$102MSep 30, 2026
Perceptive Advisors LLC1.07MUS$89.3MSep 30, 2026
Deep Track Capital, LP1.07MUS$89.1MSep 30, 2026
Remedium Capital Partners, LLC954KUS$79.5MSep 30, 2026
Westfield Capital Management Co LP830KUS$69.1MSep 30, 2026
Avidity Partners Management LP785KUS$65.4MSep 30, 2026
Summit Partners Public Asset Management, LLC724KUS$60.3MSep 30, 2026
JPMorgan696KUS$57.4MSep 30, 2026
abrdn632KUS$52.7MSep 30, 2026
Affinity Asset Advisors, LLC600KUS$50MSep 30, 2026
Goldman Sachs582KUS$48.5MSep 30, 2026
Schwab521KUS$43.4MSep 30, 2026
BNP Paribas460KUS$38.3MSep 30, 2026
Northern Trust446KUS$37.2MSep 30, 2026
UBS444KUS$37MSep 30, 2026
Voya Investment Management LLC413KUS$34.4MSep 30, 2026
Pictet Asset Management Holding SA402KUS$33.5MSep 30, 2026
Cormorant Asset Management, LP400KUS$33.3MSep 30, 2026
Adage Capital Partners Gp, L.L.C.394KUS$32.8MSep 30, 2026
Point72 Asset Management, L.P.373KUS$31.1MSep 30, 2026
Sun Life345KUS$28.7MSep 30, 2026
Candriam S.C.A.339KUS$28.3MSep 30, 2026
Braidwell LP320KUS$26.6MSep 30, 2026
Lord, Abbett & Co. LLC306KUS$25.5MSep 30, 2026
Jennison Associates LLC302KUS$25.1MSep 30, 2026
Mpm Bioimpact LLC300KUS$25MSep 30, 2026
Ghisallo Capital Management LLC300KUS$25MSep 30, 2026
Eventide Asset Management, LLC295KUS$24.6MSep 30, 2026
Holocene Advisors, LP292KUS$24.3MSep 30, 2026
Woodline Partners LP286KUS$23.8MSep 30, 2026
Bank of America281KUS$23.4MSep 30, 2026
Silverarc Capital Management, LLC248KUS$20.6MSep 30, 2026
Nuveen241KUS$20.1MSep 30, 2026
Nomura231KUS$19.3MSep 30, 2026
Blackstone Inc.220KUS$18.3MSep 30, 2026

This page holds 50 of 249 holders. Open Shareholders

Funds

HolderSharesValueAs of
Vanguard Total Stock Market Index Fund1.72MUS$164MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF1.56MUS$148MJun 30, 2026
SMALLCAP World Fund Inc1.53MUS$145MJun 30, 2026
iShares Russell 2000 ETF1.3MUS$124MJun 30, 2026
Fidelity Growth Company Fund1.22MUS$71.5MMay 31, 2026
Select Health Care Portfolio833KUS$48.8MMay 31, 2026
Fidelity Advisor Biotechnology Fund737KUS$71.2MJul 31, 2026
Fidelity Small Cap Growth Fund686KUS$66.2MJul 31, 2026
Vanguard Extended Market Index Fund581KUS$55.3MJun 30, 2026
Select Biotechnology Portfolio563KUS$32.9MMay 31, 2026
Show 50 holders
HolderSharesValueAs of
Fidelity Small Cap Index Fund551KUS$53.2MJul 31, 2026
T. Rowe Price Health Sciences Fund, Inc.451KUS$42.9MJun 30, 2026
iShares Russell 2000 Growth ETF449KUS$42.7MJun 30, 2026
Fidelity Advisor Health Care Fund428KUS$41.3MJul 31, 2026
T. Rowe Price Small-Cap Stock Fund, Inc.381KUS$36.3MJun 30, 2026
iShares Biotechnology ETF359KUS$34.2MJun 30, 2026
Fidelity Growth Company K6 Fund356KUS$20.9MMay 31, 2026
Fidelity Stock Selector Small Cap Fund345KUS$33.3MJul 31, 2026
Fidelity Series Growth Company Fund323KUS$18.9MMay 31, 2026
Harbor Small Cap Growth Fund317KUS$30.5MJul 31, 2026
Fidelity Series Small Cap Opportunities Fund301KUS$29.1MJul 31, 2026
Franklin Biotechnology Discovery Fund296KUS$28.6MJul 31, 2026
Fidelity Small Cap Growth K6 Fund296KUS$28.6MJul 31, 2026
New Economy Fund286KUS$16.7MMay 31, 2026
BlackRock Health Sciences Opportunities Portfolio265KUS$15.5MMay 29, 2026
Putnam Small Cap Growth Fund256KUS$24.3MJun 30, 2026
Fidelity Extended Market Index Fund252KUS$14.8MMay 31, 2026
JPMorgan Small Cap Growth Fund251KUS$23.9MJun 30, 2026
Eventide Healthcare & Life Sciences Fund240KUS$22.8MJun 30, 2026
Vanguard Russell 2000 Index Fund238KUS$13.9MMay 31, 2026
Schwab U.S. Small-Cap ETF235KUS$13.7MMay 31, 2026
Lord Abbett Developing Growth Fund Inc225KUS$21.7MJul 31, 2026
Janus Henderson Global Life Sciences Fund222KUS$21.1MJun 30, 2026
Franklin Small Cap Growth Fund208KUS$20.1MJul 31, 2026
T. Rowe Price Institutional Small-Cap Stock Fund205KUS$19.5MJun 30, 2026
Nomura Healthcare Fund190KUS$18.1MJun 30, 2026
Fidelity Contrafund185KUS$17.6MJun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund151KUS$14.4MJun 30, 2026
VIP Health Care Portfolio149KUS$14.2MJun 30, 2026
Fidelity Blue Chip Growth Fund129KUS$12.5MJul 31, 2026
Schwab Small-Cap Index Fund122KUS$11.8MJul 31, 2026
MFS New Discovery Value Fund122KUS$7.14MMay 31, 2026
MFS New Discovery Fund121KUS$7.11MMay 31, 2026
Fidelity SAI Small-Mid Cap Momentum Index Fund120KUS$11.6MJul 31, 2026
Strategic Advisers Fidelity U.S. Total Stock Fund109KUS$6.37MMay 31, 2026
College Retirement Equities Fund - Total Global Stock Account96,464US$9.18MJun 30, 2026
Vanguard Health Care Index Fund94,188US$5.51MMay 31, 2026
Master Small Cap Index Series92,609US$8.81MJun 30, 2026
Fidelity Total Market Index Fund92,125US$5.39MMay 31, 2026
Janus Henderson Small/Mid Cap Growth Alpha ETF82,097US$7.92MJul 31, 2026

This page holds 50 of 274 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Quinlan Paul T
Officer: General Counsel
Sale3,300USD 94.05US$310KNov 20, 2026
Quinlan Paul T
Officer: General Counsel
Sale3,000USD 94.77US$284KNov 20, 2026
Quinlan Paul T
Officer: General Counsel
Sale2,500USD 95.99US$240KNov 20, 2026
Quinlan Paul T
Officer: General Counsel
Sale200USD 96.60US$19,320Nov 20, 2026
Goncalves Joana
Officer: Chief Medical Officer
Sale2,600USD 99.52US$259KNov 16, 2026
Goncalves Joana
Officer: Chief Medical Officer
Sale1,500USD 100.48US$151KNov 16, 2026
Goncalves Joana
Officer: Chief Medical Officer
Sale1,900USD 101.53US$193KNov 16, 2026
Goncalves Joana
Officer: Chief Medical Officer
Sale300USD 102.47US$30,741Nov 16, 2026
Goncalves Joana
Officer: Chief Medical Officer
Sale200USD 103.36US$20,672Nov 16, 2026
Goncalves Joana
Officer: Chief Medical Officer
Sale500USD 105.86US$52,928Nov 16, 2026
Show 50 trades
TradeTradeSharesPriceValueDate
Ball Kristine M
Director
Sale1,196USD 102.10US$122KNov 12, 2026
Ball Kristine M
Director
Sale1,300USD 103.09US$134KNov 12, 2026
Ball Kristine M
Director
Sale2,039USD 104.16US$212KNov 12, 2026
Ball Kristine M
Director
Sale10,765USD 105.31US$1.13MNov 12, 2026
Ball Kristine M
Director
Sale2,500USD 106.05US$265KNov 12, 2026
Ball Kristine M
Director
Sale200USD 106.98US$21,397Nov 12, 2026
Agarwal Arjun
Officer: Senior Vice President, Finance
Sale500USD 101.98US$50,988Nov 12, 2026
Agarwal Arjun
Officer: Senior Vice President, Finance
Sale801USD 103.16US$82,628Nov 12, 2026
Agarwal Arjun
Officer: Senior Vice President, Finance
Sale799USD 104.25US$83,296Nov 12, 2026
Agarwal Arjun
Officer: Senior Vice President, Finance
Sale6,842USD 105.28US$720KNov 12, 2026
Agarwal Arjun
Officer: Senior Vice President, Finance
Sale958USD 106.18US$102KNov 12, 2026
Agarwal Arjun
Officer: Senior Vice President, Finance
Sale100USD 107.00US$10,700Nov 12, 2026
Klein Lawrence Otto
Director, Officer: Chief Executive Officer
Sale6,466USD 94.77US$613KNov 2, 2026
Klein Lawrence Otto
Director, Officer: Chief Executive Officer
Sale15,036USD 95.64US$1.44MNov 2, 2026
Klein Lawrence Otto
Director, Officer: Chief Executive Officer
Sale2,442USD 96.70US$236KNov 2, 2026
Klein Lawrence Otto
Director, Officer: Chief Executive Officer
Sale756USD 97.45US$73,676Nov 2, 2026
Klein Lawrence Otto
Director, Officer: Chief Executive Officer
Sale300USD 98.40US$29,521Nov 2, 2026
Quinlan Paul T
Officer: General Counsel
Sale400USD 74.90US$29,960Oct 20, 2026
Quinlan Paul T
Officer: General Counsel
Sale500USD 76.12US$38,059Oct 20, 2026
Quinlan Paul T
Officer: General Counsel
Sale1,000USD 77.20US$77,205Oct 20, 2026
Quinlan Paul T
Officer: General Counsel
Sale4,100USD 78.79US$323KOct 20, 2026
Quinlan Paul T
Officer: General Counsel
Sale3,000USD 79.49US$238KOct 20, 2026
Goncalves Joana
Officer: Chief Medical Officer
Sale2,853USD 73.89US$211KOct 15, 2026
Goncalves Joana
Officer: Chief Medical Officer
Sale1,847USD 74.69US$138KOct 15, 2026
Goncalves Joana
Officer: Chief Medical Officer
Sale1,400USD 75.48US$106KOct 15, 2026
Goncalves Joana
Officer: Chief Medical Officer
Sale700USD 76.67US$53,666Oct 15, 2026
Goncalves Joana
Officer: Chief Medical Officer
Sale200USD 77.71US$15,542Oct 15, 2026
Agarwal Arjun
Officer: Senior Vice President, Finance
Sale5,741USD 80.03US$459KOct 12, 2026
Agarwal Arjun
Officer: Senior Vice President, Finance
Sale2,100USD 80.76US$170KOct 12, 2026
Agarwal Arjun
Officer: Senior Vice President, Finance
Sale1,958USD 81.86US$160KOct 12, 2026
Agarwal Arjun
Officer: Senior Vice President, Finance
Sale200USD 82.83US$16,567Oct 12, 2026
Klein Lawrence Otto
Director, Officer: Chief Executive Officer
Sale16,246USD 83.40US$1.35MOct 1, 2026
Klein Lawrence Otto
Director, Officer: Chief Executive Officer
Sale8,554USD 84.03US$719KOct 1, 2026
Klein Lawrence Otto
Director, Officer: Chief Executive Officer
Sale200USD 84.78US$16,956Oct 1, 2026
Quinlan Paul T
Officer: General Counsel
Sale2,900USD 92.37US$268KSep 21, 2026
Quinlan Paul T
Officer: General Counsel
Sale3,832USD 93.32US$358KSep 21, 2026
Quinlan Paul T
Officer: General Counsel
Sale601USD 94.44US$56,758Sep 21, 2026
Quinlan Paul T
Officer: General Counsel
Sale2,667USD 95.31US$254KSep 21, 2026
Agarwal Arjun
Officer: Senior Vice President, Finance
Sale533USD 95.75US$51,035Sep 21, 2026
Sandler Laura Lee
Officer: Chief Operating Officer
Sale906USD 95.71US$86,713Sep 15, 2026

This page holds 50 of 128 trades. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
Fairmount Funds Management LLC19.99%13.7MApr 30, 2026Schedule 13D
Harwin Peter Evan19.50%14.6MJul 1, 2026Schedule 13D
Venrock Healthcare Capital Partners III, L.P.7.40%4.56MJun 30, 2026Schedule 13G
T. Rowe Price Investment Management, Inc.6.60%4.39MSep 30, 2026Schedule 13G
BlackRock, Inc.6.60%3.18MDec 31, 2025Schedule 13G
Capital World Investors5.60%3.4MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
James Flynn
Other companies: Lite Strategy, Inc. (Director · Since at least Oct 31, 2023); Nuvalent, Inc. (Director · Since at least Jul 28, 2021); Larimar Therapeutics, Inc. (Director · Since at least May 28, 2020); Synlogic Inc (Director · Mar 19, 2024 – Apr 26, 2025 · Past); BiomX Inc. (Director · Mar 15, 2024 – Apr 21, 2025 · Past); RiceBran Technologies (Director · Jan 3, 2024 – Jan 3, 2024 · Past); CareMax Inc (Director · Nov 17, 2022 – Nov 17, 2023 · Past); ARS Pharmaceuticals, Inc. (Director · Nov 8, 2022 – Nov 8, 2022 · Past); Da32 Life Science Tech Acquisition Corp (Director · Jul 27, 2021 – Jul 28, 2023 · Past); Oncorus Inc (Director · Oct 1, 2020 – Feb 17, 2021 · Past); Acutus Medical Inc. (Director · Aug 5, 2020 – Jan 27, 2025 · Past); Deerfield Healthcare Technology Acquisitions Corp (Director · Jul 16, 2020 – Jul 21, 2020 · Past); Q32 Bio Inc. (Director · Mar 27, 2018 – Jun 6, 2019 · Past); AdaptHealth Corp. (Director · Feb 15, 2018 – Nov 8, 2019 · Past); Alpine Immune Sciences Inc (Director · Sep 12, 2016 – Sep 12, 2016 · Past); AveXis Inc (Director · Sep 3, 2015 – Feb 10, 2016 · Past)
Director · Jan 30, 2024 – Jan 30, 2024 · Past
Ted W Love
Other companies: Lisata Therapeutics, Inc. (Director · Since at least Sep 17, 2026); Jazz Pharmaceuticals plc (Director · Since at least Dec 1, 2025); Gilead Sciences, Inc. (Director · Since at least Feb 1, 2024); Structure Therapeutics, Inc. (Director · Since at least Aug 3, 2023); Royalty Pharma plc (Director · Since at least Jul 30, 2020); Seagen Inc (Director · Aug 16, 2020 – Dec 14, 2023 · Past); Portola Pharmaceuticals Inc (Director · Sep 18, 2019 – Jul 2, 2020 · Past); Global Blood Therapeutics Inc (President and CEO, Director · Aug 11, 2015 – Oct 5, 2022 · Past); Cascadian Therapeutics Inc (Director · Sep 5, 2013 – Mar 9, 2018 · Past); Savara, Inc. (Director · Sep 5, 2012 – Jun 19, 2013 · Past); Humanigen Inc (Director · Aug 10, 2012 – Jul 10, 2015 · Past); Amicus Therapeutics Inc (Director · Jun 13, 2012 – Jun 4, 2020 · Past); Bio-Rad Laboratories, Inc. (Director · Mar 24, 2010 – Mar 24, 2010 · Past); Onyx Pharmaceuticals Inc (EVP, R&D and Tech. Operations · Feb 1, 2010 – Jul 25, 2012 · Past); Affymax Inc (Director · Dec 14, 2006 – Jun 13, 2012 · Past); Santarus Inc (Director · Jun 7, 2006 – Jan 2, 2014 · Past)
Director · Mar 7, 2006 – Feb 5, 2010 · Past
Kathryn Falberg
Other companies: Nuvation Bio Inc. (Board of Directors · Since at least Feb 10, 2021); Arcus Biosciences, Inc. (Board Member · Since at least Mar 14, 2018); The Trade Desk, Inc. (Director · Since at least Sep 20, 2016); UroGen Pharma Ltd. (Director · Jan 1, 2019 – Jun 7, 2021 · Past); Tricida Inc (Director · Jun 27, 2018 – Jun 15, 2022 · Past); Sio Gene Therapies Inc (Director · Apr 7, 2017 – May 15, 2017 · Past); BioMarin Pharmaceutical Inc. (Director · Jul 15, 2016 – Jul 15, 2016 · Past); Aimmune Therapeutics Inc (Director · Aug 5, 2015 – Oct 10, 2020 · Past); aTyr Pharma, Inc. (Director · May 6, 2015 – May 24, 2016 · Past); Medivation Inc (Director · Jan 31, 2013 – Sep 28, 2016 · Past); Jazz Pharmaceuticals plc (EVP and CFO · Dec 1, 2009 – Mar 5, 2014 · Past); Novelion Therapeutics Inc (Director · Mar 25, 2009 – May 26, 2011 · Past); Halozyme Therapeutics, Inc. (Director · May 15, 2007 – May 4, 2016 · Past)
CFO and COO · Feb 23, 2009 – Jun 25, 2009 · Past
Jean-François Formela
Other companies: Korro Bio, Inc. (Co-Founder & Director · Since at least Nov 3, 2023); ImageneBio, Inc. (Director · Mar 25, 2021 – Jun 7, 2024 · Past); Translate Bio Inc (Director · Jun 27, 2018 – Sep 14, 2021 · Past); Spero Therapeutics, Inc. (Director · Nov 1, 2017 – Aug 17, 2021 · Past); Intellia Therapeutics, Inc. (Director · May 5, 2016 – Jun 14, 2022 · Past); Egalet Corporation (Director · Feb 5, 2014 – Feb 11, 2014 · Past); Horizon Pharma PLC (Director · Jul 28, 2011 – Mar 2, 2012 · Past)
Director · Feb 10, 2012 – Oct 22, 2012 · Past
Henry Ward Wolff
Other companies: Sunesis Pharmaceuticals Inc (Director · Feb 2, 2018 – Jun 30, 2020 · Past); Calithera Biosciences, Inc. (Director · Dec 2, 2014 – Jun 1, 2022 · Past); Portola Pharmaceuticals Inc (Director · May 21, 2013 – Jul 2, 2020 · Past); Sangamo Therapeutics, Inc. (Exec VP & CFO · Jun 7, 2006 – Dec 12, 2016 · Past); Abgenix Inc (CFO & SVP, Finance · Mar 24, 2006 – Apr 1, 2006 · Past)
Sr. VP Finance and CFO · Jul 24, 2006 – Feb 1, 2007 · Past
Cameron Turtle
Other companies: Damora Therapeutics, Inc. (Board Director · Since at least Mar 23, 2026); Spyre Therapeutics, Inc. (Chief Executive Officer · Since at least Jun 22, 2023); BridgeBio Pharma, Inc. (See Remarks · Jun 27, 2019 – Dec 28, 2020 · Past); Eidos Therapeutics Inc (Chief Business Officer · Nov 5, 2018 – Jan 26, 2021 · Past)
Director · Since at least Aug 29, 2024
Kristine Ball
Other companies: Enliven Therapeutics, Inc. (Member of the Board of Directors · Since at least Oct 14, 2026); Atreca Inc (Director · May 20, 2020 – Jun 13, 2023 · Past); Forty Seven Inc (Director · Jun 27, 2018 – Apr 7, 2020 · Past); Relypsa Inc (Chief Financial Officer & SVP · Nov 14, 2013 – Sep 1, 2016 · Past)
Director · Since at least Aug 29, 2024
Samarth Kulkarni
Other companies: Centessa Pharmaceuticals PLC (Director · Since at least May 27, 2021); Black Diamond Therapeutics, Inc. (CEO, CRISPR Therapeutics AG · Since at least Jan 29, 2020); CRISPR Therapeutics AG (Chief Executive Officer and Chairman of the Board · Since at least Oct 18, 2016); Repare Therapeutics Inc (Director · Jun 18, 2020 – Jun 17, 2024 · Past)
Director · Since at least Aug 29, 2024
Barry L Zubrow
Other companies: Hudson Executive Investment Corp III (Director · Feb 23, 2021 – Feb 23, 2021 · Past); Arc Logistics Partners LP (Director · Dec 17, 2013 – Dec 21, 2017 · Past); JPMorgan Chase & Co. (Executive Vice President · Nov 30, 2007 – Oct 16, 2012 · Past)
Director · May 24, 2006 – May 31, 2007 · Past
Daniel J Mitchell
Other companies: Globeimmune Inc (Director · Jul 1, 2014 – Mar 16, 2016 · Past); Cardiovascular Systems Inc (Director · Jun 27, 2006 – Dec 12, 2008 · Past); Myogen Inc (Director · Feb 2, 2006 – Nov 17, 2006 · Past)
Director · Feb 11, 2014 – Jan 30, 2024 · Past
All 30 people
PersonSeat
Christopher Martin
Other companies: Achieve Life Sciences, Inc. (Director · Since at least May 11, 2026); Edgewise Therapeutics, Inc. (Director · Since at least Nov 19, 2025)
Director · Since at least Dec 11, 2025
Peter Harwin
Other companies: Cogent Biosciences, Inc. (Founding Partner, Fairmount Funds Management LLC · Since at least Nov 4, 2026); Damora Therapeutics, Inc. (Chairman of the Board · Since at least May 12, 2026)
Director · Since at least Nov 5, 2026
Carl Dambkowski
Other companies: Apogee Therapeutics, Inc. (Chief Medical Officer · Since at least Apr 2, 2025)
Director · Since at least Jun 2, 2025
John L Zabriskie
Other companies: Macrochem Corp (Director · Sep 5, 2007 – Sep 5, 2007 · Past)
Director · Jan 27, 2009 – Sep 17, 2013 · Past
Robert E Conway
Other companies: Alpine Immune Sciences Inc (Director · Jun 16, 2015 – May 20, 2024 · Past)
Director · Sep 3, 2013 – Jan 30, 2024 · Past
Anders D HoveDirector · Mar 1, 2018 – Jan 30, 2024 · Past
Arjun AgarwalSenior Vice President, Finance · Since at least Aug 29, 2024
Chris MartinDirector · Since at least Dec 11, 2025
Christopher David OzeroffS.V.P., General Counsel · May 26, 2010 – Dec 14, 2021 · Past
C Jeffrey DekkerChief Financial Officer · May 10, 2021 – Dec 8, 2022 · Past
E Lee BendekgeyCFO and Treasurer · Aug 1, 2006 – Dec 31, 2008 · Past
Joana GoncalvesChief Medical Officer · Since at least Apr 15, 2026
Larry Todd EdwardsChief Commercial Officer · Since at least Aug 24, 2026
Laura Lee SandlerChief Operating Officer · Since at least Jul 1, 2025
Michael R BristowPres. & Chief Executive Offic, Director · Dec 21, 2020 – Dec 14, 2021 · Past
Patrick M WheelerChief Financial Officer · Dec 7, 2009 – Sep 18, 2014 · Past
Paul T QuinlanGeneral Counsel · Since at least Jun 15, 2026
Randall St LaurentEVP Commercial Operations · Jan 27, 2009 – Jan 27, 2009 · Past
Thomas A KeuerChief Operating Officer · Dec 8, 2022 – Dec 8, 2022 · Past
Todd EdwardsChief Commercial Officer · Since Aug 24, 2026

Open People

Log in to ask 6ix AI your own questions about Oruka Therapeutics, Inc.